The Bull Case For Estée Lauder Companies (EL) Could Change Following Glimmer’s Youth-Focused Hailee Steinfeld Launch

• In late July 2026, Estée Lauder announced Glimmer, a new prestige amber floral fragrance with a gourmand twist, supported by a global TV, print, digital, in-store, and outdoor campaign fronted by Hailee Steinfeld, with Glimmer Eau de Parfum priced at US$130 for 50ml and US$160 for 100ml from its August 2026 launch.
• Alongside news of director Jennifer Hyman’s planned November 2026 retirement from the Board, the Glimmer launch highlights Estée Lauder’s push to engage a younger consumer base through a high-profile, emotion-driven fragrance narrative.
• Next, we’ll examine how Glimmer’s Hailee Steinfeld-led campaign aimed at younger consumers reshapes Estée Lauder’s existing investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Estée Lauder Companies Investment Narrative Recap

To own Estée Lauder today, you need to believe that premium beauty brands and new product launches can justify ongoing investment in marketing and innovation, despite recent earnings volatility and high fixed costs. The Glimmer launch looks directionally aligned with that thesis but is unlikely to change the near term picture on the key catalyst of margin recovery or the biggest current risk around weaker demand in core regions and travel retail.

Among recent announcements, the planned November 2026 retirement of director Jennifer Hyman stands out beside Glimmer. While not directly tied to product performance, it comes as Estée Lauder continues its Profit Recovery and Growth Plan and board level oversight of restructuring, which many investors watch closely as a potential driver of improved profitability and as a counterweight to the risk of elevated SG&A and restructuring charges.

Yet, against this push for a younger fragrance audience, investors still need to be aware of the risk that prolonged travel retail weakness could...

Read the full narrative on Estée Lauder Companies (it's free!)

Estée Lauder Companies' narrative projects $16.5 billion revenue and $1.4 billion earnings by 2029.

Uncover how Estée Lauder Companies' forecasts yield a $95.12 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting revenue near US$17.4 billion and earnings around US$1.9 billion by 2029, which reflects a far more upbeat view of margin recovery than consensus. Those forecasts, together with the idea that AI driven personalization could accelerate market share gains, show how widely opinions can differ and how launches like Glimmer may eventually shift both the bullish and more cautious narratives over time.

Explore 5 other fair value estimates on Estée Lauder Companies - why the stock might be worth as much as 55% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Estée Lauder Companies research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Estée Lauder Companies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Estée Lauder Companies' overall financial health at a glance.

Seeking Other Investments?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com